MARKET

MNKKQ

MNKKQ

Mallinckrodt Plc
OTCPK

Real-time Quotes | Nasdaq Last Sale

0.077
-0.020
-20.82%
Closed 14:14 05/20 EDT
OPEN
0.088
PREV CLOSE
0.097
HIGH
0.088
LOW
0.075
VOLUME
97.86K
TURNOVER
8.21K
52 WEEK HIGH
0.590
52 WEEK LOW
0.051
MARKET CAP
6.51M
P/E (TTM)
-0.0097
1D
5D
1M
3M
1Y
5Y
New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomati...
PR Newswire · 3d ago
BRIEF-High Court Of Ireland Confirms Mallinckrodt Scheme Of Arrangement
reuters.com · 04/27 12:10
High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement
Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that the High Court of Ireland (the "Irish High Court") has made an Order confirming the scheme of arrangement between the Company, its creditors and members (the "Scheme")...
PR Newswire · 04/27 12:05
Mallinckrodt announces real-world data on use of inhaled nitric oxide in COVID patients
Mallinckrodt (NYSE:MNK) (OTCPK:MNKKQ) reported data from a retrospective chart review study evaluating the real-world use INOmax (nitric oxide) gas for inhalation in hospitalized patients with COVID-19 and mild-to-moderate acute respiratory
Seekingalpha · 04/13 11:26
BRIEF-Mallinckrodt Announces Publication Of Data From Study On Investigational Use Of Inhaled Nitric Oxide In Covid-19 Patients
reuters.com · 04/13 10:48
Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context
Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar® Gel (repository corticotropin injecti...
PR Newswire · 03/28 10:45
Silence Therapeutics to get $3M from Mallinckrodt as trial application for SLN501 filed
Silence Therapeutics plc (NASDAQ:SLN) will receive a $3M research milestone payment from Mallinckrodt (OTCPK:MNKKQ) as the companies announced filing of a clinical trial application (CTA) for SLN501 targeting complement-mediated diseases. In July
Seekingalpha · 03/23 11:57
Silence Therapeutics And Mallinckrodt Announce Submission Of Clinical Trial Application For SLN501; Silence To Receive $3M Milestone Payment
Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 LONDON & DUBLIN--(BUSINESS WIRE)-- Silence Therapeutics plc (NASDAQ:SLN), a
Benzinga · 03/23 11:21
More
No Data
Learn about the latest financial forecast of MNKKQ. Analyze the recent business situations of Mallinckrodt Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MNKKQ stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
High1.500
Average1.500
Low1.500
Current 0.0768
EPS
Actual
Estimate
-2.05-0.910.221.35
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 335
Institutional Holdings: 102.15M
% Owned: 120.57%
Shares Outstanding: 84.72M
TypeInstitutionsShares
Increased
86
13.07M
New
48
7.97M
Decreased
92
12.11M
Sold Out
72
4.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.90%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Angus Russell
President/Chief Executive Officer/Director
Mark Trudeau
Chief Financial Officer/Executive Vice President
Bryan Reasons
Chief Human Resource Officer/Executive Vice President
Ian Watkins
Executive Vice President/Chief Scientific Officer
Steven Romano
Executive Vice President
Mark Casey
Executive Vice President
Hugh O'Neill
Independent Director
David Carlucci
Independent Director
J. Martin Carroll
Independent Director
Paul Carter
Independent Director
David Norton
Independent Director
Carlos Paya
Independent Director
JoAnn Reed
Independent Director
Anne Whitaker
Independent Director
Kneeland Youngblood
No Data
No Data
About MNKKQ
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Webull offers kinds of Mallinckrodt PLC stock information, including OTCPK:MNKKQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKKQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKKQ stock methods without spending real money on the virtual paper trading platform.